日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC

新型人类 EML4-ALK 融合细胞系鉴定出核苷酸还原酶 RRM2 是 NSCLC 中活化 ALK 的靶点

A A Bokhari, W-Y Lai, A T Le, J L Gabre, T-P Chuang, S Fransson, B Bergman, A Djos, N Chen, T Martinsson, J Van den Eynden, R C Doebele, R H Palmer, B Hallberg, G Umapathy

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

ALK 抑制剂 PF-06463922 作为单一药物,可有效治疗由 ALK 和 MYCN 表达驱动的神经母细胞瘤

J Guan, E R Tucker, H Wan, D Chand, L S Danielson, K Ruuth, A El Wakil, B Witek, Y Jamin, G Umapathy, S P Robinson, T W Johnson, T Smeal, T Martinsson, L Chesler, R H Palmer, B Hallberg